2,3-difluoro-4-methylbenzoic acid tert-butyl ester | 1203662-45-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3-difluoro-4-methylbenzoic acid tert-butyl ester
• 英文别名: 2,3-Difluoro-4-methyl-benzoic acid tert-butyl ester；tert-butyl 2,3-difluoro-4-methylbenzoate
• CAS: 1203662-45-6
• 化学式: C₁₂H₁₄F₂O₂
• 分子量: 228.239
• InChiKey: RAFRCYFBQXEZFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,3-difluoro-4-methylbenzoic acid tert-butyl ester 在 N-溴代丁二酰亚胺(NBS) 、 磺酰氯 、 偶氮二异丁腈 、 十二/十四烷基二甲基氧化胺 、 potassium tert-butylate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 四氯化碳 、 正己烷 、 二氯甲烷 、 水 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 58.33h， 生成 7-[(2-fluoro-4-iodophenyl)amino]benzo[d]isothiazole-6-carboxylic acid (2-vinyloxyethoxy)amide
  参考文献：
  名称：

  Discovery of Novel Allosteric Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors Possessing Bidentate Ser212 Interactions

  摘要：

  Using structure-based design, two novel series of highly potent biaryl amine mitogen-activated protein kinase kinase (MEK) inhibitors have been discovered. These series contain an H-bond acceptor, in a shifted position compared with previously disclosed compounds, and an adjacent H-bond donor, resulting in a bidentate interaction with the Ser212 residue of MEK1. The most potent compound identified, 1 (G-894), is orally active in in vivo pharmacodynamic and tumor xenograft models.

  DOI：

  10.1021/jm2017094
• 作为产物：
  描述：

  2,3-二氟-4-甲基苯甲酸 、 叔丁醇 在 4-二甲氨基吡啶 、 二碳酸二叔丁酯 作用下， 反应 5.0h， 以65%的产率得到2,3-difluoro-4-methylbenzoic acid tert-butyl ester
  参考文献：
  名称：

  Discovery of Novel Allosteric Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors Possessing Bidentate Ser212 Interactions

  摘要：

  Using structure-based design, two novel series of highly potent biaryl amine mitogen-activated protein kinase kinase (MEK) inhibitors have been discovered. These series contain an H-bond acceptor, in a shifted position compared with previously disclosed compounds, and an adjacent H-bond donor, resulting in a bidentate interaction with the Ser212 residue of MEK1. The most potent compound identified, 1 (G-894), is orally active in in vivo pharmacodynamic and tumor xenograft models.

  DOI：

  10.1021/jm2017094

文献信息

• [EN] BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS<br/>[FR] HÉTÉROCYCLES BICYCLIQUES EN TANT QU'INHIBITEURS DE MEK KINASE
  申请人：GENENTECH INC

  公开号：WO2010003025A1

  公开（公告）日：2010-01-07

  The invention relates to bicyclic heterocycles of formulae I and II with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  该发明涉及具有抗癌和/或抗炎活性的式I和式II的双环杂环化合物，更具体地具有MEK激酶抑制活性。该发明提供了用于抑制异常细胞生长、治疗过度增殖性疾病或治疗哺乳动物炎症性疾病的组合物和方法。该发明还涉及使用这些化合物进行体外、体内和体内诊断或治疗哺乳动物细胞或相关病理条件的方法。
• BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS
  申请人：Heald Robert Andrew

  公开号：US20110190257A1

  公开（公告）日：2011-08-04

  The invention relates to bicyclic heterocycles of formulae I and II with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及公式I和II的双环杂环化合物，具有抗癌和/或抗炎活性，更具有MEK激酶抑制活性。 本发明提供了用于抑制异常细胞生长，治疗增殖过度性疾病或治疗哺乳动物的炎症性疾病的组合物和方法。 本发明还涉及使用该化合物进行哺乳动物细胞的体外，体内和原位诊断或治疗，或相关病理情况的方法。
• Bicyclic heterocycles as MEK kinase inhibitors
  申请人：Heald Robert A.

  公开号：US08841462B2

  公开（公告）日：2014-09-23

  The invention relates to bicyclic heterocycles of formulae I and II with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及公式I和II的双环杂环化合物，具有抗癌和/或抗炎活性，更具有MEK激酶抑制活性。本发明提供了用于抑制异常细胞生长、治疗过度增殖性疾病或治疗哺乳动物的炎症性疾病的组合物和方法。本发明还涉及使用该化合物进行哺乳动物细胞的体外、原位和体内诊断或治疗，或相关病理条件的方法。
• US8841462B2
  申请人：——

  公开号：US8841462B2

  公开（公告）日：2014-09-23
• Discovery of Novel Allosteric Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors Possessing Bidentate Ser212 Interactions
  作者：Robert A. Heald、Philip Jackson、Pascal Savy、Mark Jones、Emanuela Gancia、Brenda Burton、Richard Newman、Jason Boggs、Emily Chan、Jocelyn Chan、Edna Choo、Mark Merchant、Patrick Rudewicz、Mark Ultsch、Christian Wiesmann、Qin Yue、Marcia Belvin、Steve Price

  DOI：10.1021/jm2017094

  日期：2012.5.24

  Using structure-based design, two novel series of highly potent biaryl amine mitogen-activated protein kinase kinase (MEK) inhibitors have been discovered. These series contain an H-bond acceptor, in a shifted position compared with previously disclosed compounds, and an adjacent H-bond donor, resulting in a bidentate interaction with the Ser212 residue of MEK1. The most potent compound identified, 1 (G-894), is orally active in in vivo pharmacodynamic and tumor xenograft models.